跳到正文
OurGMP· 荀令君18·· 2 天前AI 评分70

FDA 对赛默飞世尔新加坡 TFBS 厂签发 483,列出两项观察

赛默飞世尔新加坡FDA 483

AI 导读

FDA 于 2026 年 5 月 5 日向赛默飞世尔新加坡 TFBS 厂签发 483,正文共 3 页、列 2 项观察,检查日期为 2026 年 4 月 27 日至 5 月 5 日。

正文
微信视频号封面
微信视频号 · OurGMP

赛默飞世尔新加坡FDA 483解读
#FDA #483

在微信原文观看视频号

受检企业:Thermo Fisher Biopharma Services PTE. LTD (TFBS),新加坡

检查日期:2026/4/27–5/5

签发日期:2026/5/5 原文共 3 页、2 项观察

DURING AN INSPECTION OF YOUR FIRM, WE OBSERVED:

在对贵公司进行检查期间,我们观察到:

OBSERVATION 1 观察项 1(原文第 1–2 页)

The visual inspection program for (b)(4) drug product (b)(4) manufactured at the TFBS facility is inadequate. Specifically:

TFBS 厂区生产的 (b)(4) 药品 (b)(4) 的目视检查(灯检)程序不充分。具体如下:

A. Defects identified during 100% visual inspection, including those with the potential to compromise container closure integrity and product sterility, have not been adequately trended or investigated to determine root causes and implement appropriate corrective and preventive actions (CAPAs).

A. 在 100% 目视检查中发现的缺陷,包括可能损害容器密封完整性与产品无菌性的缺陷,未进行充分的趋势分析或调查,以确定根本原因并实施相应的纠正与预防措施(CAPA)。

A significant upward trend in the percentage of particulate defects has been observed from the engineering batch through the process performance qualification (PPQ) batches. These particles—including white particles, white fibers, and colored particles—are categorized by your firm as critical defects. The observed increase in particulate contamination has not been investigated.

从工程批到工艺性能确认(PPQ)批,微粒缺陷占比呈显著上升趋势。贵公司将这些微粒——包括白色微粒、白色纤维及有色微粒——归类为关键缺陷。所观察到的微粒污染增加尚未开展调查。

B. A recurring container defect, identified as a "Check," was observed at a significant frequency during the second PPQ campaign. This defect is categorized as major (length ≥ (b)(4) mm) or minor (length between (b)(4) mm and (b)(4) mm). Despite its recurrence, this defect has not been investigated to determine its root cause.

B. 在第二轮 PPQ 活动期间,以较高频次反复出现一种被标识为 "Check"(裂痕类)的容器缺陷。该缺陷按长度归为主要缺陷(长度 ≥ (b)(4) mm)或次要缺陷(长度介于 (b)(4) mm 与 (b)(4) mm 之间)。尽管该缺陷反复出现,仍未开展调查以确定其根本原因。

C. Multiple batches out of (b)(4) have failed to meet the established Acceptable Quality Limit (AQL) for critical defects, which your procedure SOP-000521068 states have an acceptance number of (b)(4). The recurrence of these failures demonstrates the deficiencies in the visual inspection program.

C. 在 (b)(4) 中有多个批次未能达到既定的关键缺陷可接受质量限(AQL);贵公司规程 SOP-000521068 规定其接收数为 (b)(4)。此类不合格反复发生,反映出目视检查程序存在缺陷。

OBSERVATION 2 观察项 2(原文第 3 页)

Your manufacturing process for (b)(4) drug product is not consistently producing a product that meets its established specifications. This is evidenced by a significant number of batch rejections, process deviations, and invalidated qualification runs.

贵公司 (b)(4) 药品的生产工艺未能持续生产出符合既定质量标准的产品。大量批次拒收、工艺偏差以及确认运行被判定无效即为明证。

A. (b)(4) out of the (b)(4) drug product PPQ batches manufactured to date have been rejected. (b)(4)

A. 迄今生产的 (b)(4) 个药品 PPQ 批次中,有 (b)(4) 个批次被拒收。

B. Your Aseptic Process Simulations (APS), intended to qualify your aseptic process, have been repeatedly invalidated or aborted due to process failures, including media leakage (QR#1019604), breakage of vials (QR#1067037), and atypical rejects at the stopper inspection station (QR#1272483).

B. 贵公司用于确认无菌工艺的无菌工艺模拟(APS)因工艺失效被反复判定无效或中止,包括培养基泄漏(QR#1019604)、西林瓶破损(QR#1067037)以及胶塞检查工位出现异常剔除(QR#1272483)。

C. The manufacturing of a post-PPQ batch was delayed on April 28 due to a malfunction of the particle monitoring system. Manufacturing of this batch did not resume until April 29.

C. 某一PPQ后批次因粒子监测系统故障于 4 月 28 日延迟生产,直至 4 月 29 日方恢复该批次的生产。

来听一听看一看近期公布国内企业的FDA 483吧!

近期FDA发布的MNC的FDA 483汇总

来源:OurGMP · mp.weixin.qq.com